funkee
All Star
Still dipping. Why you think? I've got a few extra G's to spare, tell me more why I should buy,
Last edited:
Down but about to rebound? Only stock picks
- Thread starter morris
- Start date
Still dipping. Why you think? I've got a few extra G's to spare, tell me more why I should buy,
ahomeplateslugger
Superstar
They took a big dip because they reported their first loss since 2005 but that’s becuse they were spending A LOT on expanding, AI and operations. They showcased their first self driving car this year at a Vegas tech convention and I believe they’re the leading Chinese company in that field. This company is going to continue to grow from here. Great return at this price. They’ll for sure rebound imo.
You can buy some now then wait a week or two to see if it dips to buy more.
Ghostface Trillah
God-level poster
Nah..I was up nealry 40%
win some/lose some....other than this, DBI and one other it's been a real decent year so far.
Now ... what about NIO?
Buy or hell no?
Ghostface Trillah
God-level poster
It ain't about how much you was up, it's about where you're at. I fell victim to the tech stock drop before so i know how it goes.
Haven't looked into NIO. I don't know why it dropped or what they have that an bring it back up. If you do then that will tell you which way to go.
Nio is like Tesla but they don’t manufacture their own cars. They were supposed to start on a factory this year but backed out.
China cut the subsidies down on EVs last I heard. EVs might be the future but right now they’re a niche product and as Tesla can attest when the government cuts the subsidies sales decline as a result and demand drops.
you bought it or buying it?
hmmm.
I see they went from $2.76 to the high teens in under a year (Sept. of 2018). You see it spiking that high again (8x more to$108 levels)?
Right now, they are a very small company w/ a potentially blockbuster drug. Im thinking (hoping) for a buyout soon at a very nice premium.
If no, buyout, I think well see a price near $100 in 2021, if not earlier.
Amarin (AMRN) submitted its supplemental new drug application (sNDA) for Vascepa on March 28th. Given the FDA review timeline, there are upcoming catalysts for this filing that could weigh heavily on the near and long term stock price for this potential blockbuster drug and company. Furthermore, I believe that Amarin already has some indications from the FDA whether they will receive priority or standard review.
INVESTOR ALERT: Why Amarin May Already Know Their Chances of Receiving Priority Review – MS Money Moves
INVESTOR ALERT: Why Amarin May Already Know Their Chances of Receiving Priority Review – MS Money Moves